News
EDA, community partners fund ‘virtual hospital’ at the UT Health Science Center San Antonio
SAN ANTONIO - A $1 million grant from the Economic Development Administration (EDA) and funding from ...
National Trauma Institute Seeks To Stop The Bleeding With Dramatic Campaign In Times Square
(SAN ANTONIO) – The National Trauma Institute (NTI), a non-profit organization dedicated to funding ...
Events
16th Annual Trauma Symposium
16th Annual Trauma SymposiumAug. 30 – Sept. 1, 2010Marriott RivercenterSan Antonio, Texas A ...Save the Date for the Annual Julio Palmaz Award Dinner
Save The Date 5th Annual Julio Palmaz Award Dinner. Honoring a local biomedical innovator.Thursday, ...Industry Publications
The Mission
The Mission is published by the University of Texas Health Science Center.
UTSA Discovery
UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...
San Antonio Business Journal
The U.S. Patent and Trademark Office issued a new patent to GenSpera Inc. to cover the intellectual property on the company’s second anti-cancer drug compound currently in development.
The patent 7,635,682 covers GenSpera’s drug G-115 — which is activated in prostate tumors by an enzyme. In preclinical testing, G-115 was shown to inhibit the growth of tumors in animal models of prostate cancer. Obtaining the patent rights to this drug is key as GenSpera seeks formal Food and Drug Administration approval.
GenSpera’s President and CEO Craig Dionne says that the term of the patent will extend into 2026. This will give the company time to enter into discussions with future development partners.
San Antonio-based GenSpera is a development stage oncology company with a technology platform that delivers drugs directly into tumors.
